Thus, the combined data obtained in this in vivo study on cervical cancer CC-5 and melanoma B-16, as well as the data obtained in our first study of T1084 on solid Ehrlich carcinoma [40], indicate that the pharmacodynamics of T1084 antitumor action develop through the interaction of NOS-dependent and PDK-dependent pathophysiological effects of this NOS/PDK inhibitor. The gene discussed is NOS1; the disease is cervical cancer.